uniQure N.V. Files 8-K Report
Ticker: QURE · Form: 8-K · Filed: Aug 15, 2024 · CIK: 1590560
| Field | Detail |
|---|---|
| Company | Uniqure N.V. (QURE) |
| Form Type | 8-K |
| Filed Date | Aug 15, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulation-fd
TL;DR
uniQure filed an 8-K, likely containing important updates for investors.
AI Summary
On August 15, 2024, uniQure N.V. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events beyond the filing itself were detailed in the provided text.
Why It Matters
This filing indicates uniQure N.V. is providing updates or disclosures required by the SEC, which could contain important information for investors.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification and does not contain specific material events or financial data that would indicate a change in risk.
Key Players & Entities
- uniQure N.V. (company) — Registrant
- August 15, 2024 (date) — Date of earliest event reported
- 0001558370-24-012295 (filing_id) — Accession Number
- Paasheuvelweg 25a, 1105 BP Amsterdam, The Netherlands (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by uniQure N.V.?
The filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported was on August 15, 2024.
What is uniQure N.V.'s principal executive office address?
The principal executive offices are located at Paasheuvelweg 25a, 1105 BP Amsterdam, The Netherlands.
What is the Commission File Number for uniQure N.V.?
The Commission File Number is 001-36294.
What is the standard industrial classification for uniQure N.V.?
The standard industrial classification is PHARMACEUTICAL PREPARATIONS [2834].
Filing Stats: 545 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2024-08-15 07:48:04
Filing Documents
- qure-20240815x8k.htm (8-K) — 34KB
- qure-20240815xex99d1.htm (EX-99.1) — 18KB
- qure-20240815xex99d1001.jpg (GRAPHIC) — 6KB
- 0001558370-24-012295.txt ( ) — 179KB
- qure-20240815.xsd (EX-101.SCH) — 3KB
- qure-20240815_lab.xml (EX-101.LAB) — 15KB
- qure-20240815_pre.xml (EX-101.PRE) — 10KB
- qure-20240815x8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On August 15, 2024, uniQure N.V. (the " Company ") issued a press release announcing the dosing of the first patient in the Company's Phase I/IIa clinical trial of AMT-191 for the treatment of Fabry disease. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information provided in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liability of such section, nor shall it be incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended (the " Securities Act "), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of uniQure N.V. dated August 15, 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. UNIQURE N.V. Date: August 15, 2024 By: /s/ Jeannette Potts JEANNETTE POTTS Chief Legal and Compliance Officer